762900login-checkSparsentan Failed to Preserve Kidney Function Over Time in FSGS |
— However, more patients on the drug achieved partial remission of proteinuria vs irbesartan
By Kristen Monaco
PHILADELPHIA — Treatment with sparsentan (Filspari) led to no significant differences in estimated glomerular filtration rate (eGFR) slope compared with irbesartan among patients with focal segmental glomerulosclerosis (FSGS), the phase III DUPLEX trial showed.
Read the full article in MedPage Today.
762900login-checkSparsentan Failed to Preserve Kidney Function Over Time in FSGS |